A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


June 25, 2013

Access to Meds to Treat Drug Addiction Is Vastly Limited

Because of restrictions of Medicaid programs and insurance companies, medications to treat addiction to opiates are often inaccessible to those who need them, MedPage Today reports. The American Society of Addiction Medicine (ASAM) released a 216-page report on this issue, which is critical to the HIV epidemic because injection drug use is a major contributing factor to the virus’s spread. (Heroin, for example, is an opiate.)

The report found that access to these prescription treatments varies widely between state Medicaid programs, with just 28 covering all three of the medications Probuphine (buprenorphine), methadone and Vivitrol (naltrexone); all are approved by the U.S. Food and Drug Administration (FDA). Forty-two state Medicaid programs require prior authorization for buprenorphine. Many of the programs also impose coverage limits for lifetime benefits.

The report finds that there are similar restrictions on treatment coverage among private insurance companies and that coverage is sparse for such drugs as Suboxone (buprenorphine/naloxone) and injectable naltrexone.

Congress also imposes limits on the number of patients a clinician can treat at one time. Furthermore, the Drug Addiction Treatment Act of 2000 requires that care providers obtain a special Drug Enforcement Administration waiver to prescribe certain drugs to treat opioid addiction.

To read the MedPage Today report, click here.

To read the ASAM report, click here.

Search: Opiate, addiction, treatment, Medicaid, private insurer, American Society of Addiction Medicine, ASAM, Probuphine, buprenorphine, methadone, Vivitrol, naltrexone, buprenorphine, Suboxone, naloxone, Drug Addiction Treatment Act of 2000.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.